Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Ueda, Shigeto ^a   Kondoh, Nobuo ^b   Tsuda, Hitoshi ^a   Yamamoto, Souhei ^a   Asakawa, Hideki ^a   Fukatsu, Kazuhiko ^a   Kobayashi, Takayuki ^a   Yamamoto, Junji ^a   Tamura, Katsumi ^c   Ishida, Jiro ^c   Abe, Yoshiyuki ^c   Yamamoto, Mikio ^a   Mochizuki, Hidetaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b ASAHI UNIVERSITY   (Japan)

^c Tokorozawa PET Diagnostic Imaging Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CELL CYCLE PROTEIN 6; CENTROMERE PROTEIN F; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; NUCLEAR PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CDC6 PROTEIN, HUMAN; CELL CYCLE PROTEIN; NONHISTONE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DNA MICROARRAY; DRUG TUMOR LEVEL; GENE EXPRESSION; GENE IDENTIFICATION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PROGNOSIS; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR VOLUME; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; RADIOGRAPHY; REPRODUCIBILITY; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, DUCTAL, BREAST; CELL CYCLE PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; DATA INTERPRETATION, STATISTICAL; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFILAMENT PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 60649115455     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-384     Document Type: Article

References (32)

1. Rauschecker H Clarke M Gatzemeier W Recht A Systemic therapy for treating locoregional recurrence in women with breast cancer Cochrane Database Syst Rev 2001, 4:CD002195 11687148
2. Goldhirsch A Wood WC Gelber RD Coates AS Thurlimann B Senn HJ Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 2007, 18(7):1133-1144 10.1093/annonc/mdm271 17675394
3. Charlson ME Feinstein AR Rate of disease progression in breast cancer: A clinical estimate of prognosis within nodal and anatomic stages J Natl Cancer Inst 1984, 72(2):225-231 6582311
4. Paik S Shak S Tang G Kim C Baker J Cronin M Baehner FL Walker MG Watson D Park T et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 2004, 351(27):2817-2826 10.1056/NEJMoa041588 15591335
5. van't Veer LJ Dai H Vijver van de MJ He YD Hart AA Mao M Peterse HL Kooy van der K Marton MJ Witteveen AT et al. Gene expression profiling predicts clinical outcome of breast cancer Nature 2002, 415(6871):530-536 10.1038/415530a 11823860
6. Perreard L Fan C Quackenbush JF Mullins M Gauthier NP Nelson E Mone M Hansen H Buys SS Rasmussen K et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay Breast Cancer Res 2006, 8(2):R23 1557722 16626501 10.1186/bcr1399
7. Juweid ME Cheson BD Positron-emission tomography and assessment of cancer therapy N Engl J Med 2006, 354(5):496-507 10.1056/NEJMra050276 16452561
8. Weber WA Ziegler SI Thodtmann R Hanauske AR Schwaiger M Reproducibility of metabolic measurements in malignant tumors using FDG PET J Nucl Med 1999, 40(11):1771-1777 10565769
9. Ueda S Tsuda H Asakawa H Shigekawa T Fukatsu K Kondo N Yamamoto M Hama Y Tamura K Ishida J et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/ computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer Jpn J Clin Oncol 2008, 38(4):250-258 10.1093/jjco/hyn019 18407934
10. Higashi K Ueda Y Arisaka Y Sakuma T Nambu Y Oguchi M Seki H Taki S Tonami H Yamamoto I 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer J Nucl Med 2002, 43(1):39-45 11801701
11. Vesselle H Schmidt RA Pugsley JM Li M Kohlmyer SG Vallires E Wood DE Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography Clin Cancer Res 2000, 6(10):3837-3844 11051227
12. Nakamoto Y Saga T Fujii S Positron emission tomography application for gynecologic tumors Int J Gynecol Cancer 2005, 15(5):701-709 10.1111/ j.1525-1438.2005.00245.x 16174216
13. Buck A Schirrmeister H Kuhn T Shen C Kalker T Kotzerke J Dankerl A Glatting G Reske S Mattfeldt T FDG uptake in breast cancer: Correlation with biological and clinical prognostic parameters Eur J Nucl Med Mol Imaging 2002, 29(10):1317-1323 10.1007/s00259-002-0880-8 12271413
14. Arai M Kondoh N Imazeki N Hada A Hatsuse K Kimura F Matsubara O Mori K Wakatsuki T Yamamoto M Transformation-associated gene regulation by ATF6alpha during hepatocarcinogenesis FEBS Lett 2006, 580(1):184-190 10.1016/j.febslet.2005.11.072 16364319
15. Kondoh N Ohkura S Arai M Hada A Ishikawa T Yamazaki Y Shindoh M Takahashi M Kitagawa Y Matsubara O et al. Gene expression signatures that can discriminate oral leukoplakia subtypes and squamous cell carcinoma Oral Oncol 2007, 43(5):455-462 10.1016/ j.oraloncology.2006.04.012 16979924
16. Ueda S Tsuda H Sato K Takeuchi H Shigekawa T Matsubara O Hiraide H Mochizuki H Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1 Cancer Sci 2006, 97(7):597-604 10.1111/j.1349-7006.2006.00228.x 16827799
17. Iwaya K Tsuda H Hiraide H Tamaki K Tamakuma S Fukutomi T Mukai K Hirohashi S Nuclear p53 immunoreaction associated with poor prognosis of breast cancer Jpn J Cancer Res 1991, 82(7):835-840 1679056
18. Buck AK Schirrmeister H Mattfeldt T Reske SN Biological characterisation of breast cancer by means of PET Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S80-87 10.1007/s00259-004-1529-6 15127240
19. Bos R Hoeven van Der JJ Wall van Der E Groep van Der P van Diest PJ Comans EF Joshi U Semenza GL Hoekstra OS Lammertsma AA et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J Clin Oncol 2002, 20(2):379-387 10.1200/JCO.20.2.379 11786564
20. Avril N Menzel M Dose J Schelling M Weber W Janicke F Nathrath W Schwaiger M Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis J Nucl Med 2001, 42(1):9-16 11197987
21. Liao H Winkfein RJ Mack G Rattner JB Yen TJ CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis J Cell Biol 1995, 130(3):507-518 2120529 7542657 10.1083/jcb.130.3.507
22. O'Brien SL Fagan A Fox EJ Millikan RC Culhane AC Brennan DJ McCann AH Hegarty S Moyna S Duffy MJ et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer Int J Cancer 2007, 120(7):1434-1443 10.1002/ijc.22413 17205517
23. Hall JR Kow E Nevis KR Lu CK Luce KS Zhong Q Cook JG Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage Mol Biol Cell 2007, 18(9):3340-3350 1951745 17567951 10.1091/mbc.E07-02-0173
24. Duursma A Agami R p53-Dependent regulation of Cdc6 protein stability controls cellular proliferation Mol Cell Biol 2005, 25(16):6937-6947 1190229 16055707 10.1128/MCB.25.16.6937-6947.2005
25. Fujita M Yamada C Goto H Yokoyama N Kuzushima K Inagaki M Tsurumi T Cell cycle regulation of human CDC6 protein. Intracellular localization, interaction with the human mcm complex, and CDC2 kinase-mediated hyperphosphorylation J Biol Chem 1999, 274(36):25927-25932 10.1074/ jbc.274.36.25927 10464337
26. Clay-Farrace L Pelizon C Santamaria D Pines J Laskey RA Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1 Embo J 2003, 22(3):704-712 140731 12554670 10.1093/ emboj/cdg046
27. Harris L Fritsche H Mennel R Norton L Ravdin P Taube S Somerfield MR Hayes DF Bast RC Jr American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 2007, 25(33):5287-5312 10.1200/JCO.2007.14.2364 17954709
28. Clark GM Allred DC Hilsenbeck SG Chamness GC Osborne CK Jones D Lee WH Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer Cancer Res 1997, 57(24):5505-5508 9407959
29. Ohta S Koide M Tokuyama T Yokota N Nishizawa S Namba H Cdc6 expression as a marker of proliferative activity in brain tumors Oncol Rep 2001, 8(5):1063-1066 11496317
30. Murphy N Ring M Heffron CC King B Killalea AG Hughes C Martin CM McGuinness E Sheils O O'Leary JJ p16INK4A, CDC6, and MCM5: Predictive biomarkers in cervical preinvasive neoplasia and cervical cancer J Clin Pathol 2005, 58(5):525-534 1770660 15858126 10.1136/jcp.2004.018895
31. Tsuda H Iwaya K Fukutomi T Hirohashi S p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade Jpn J Cancer Res 1993, 84(4):394-401 8099903
32. Tsuda H Hirohashi S Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer Int J Cancer 1994, 57(4):498-503 10.1002/ijc.2910570410 7910151